Ipsen scuttles liver disease candidates from $952M Albireo acquisition

Ipsen has set aside the two drug candidates it picked up from the 2023 acquisition of liver disease specialist Albireo, with one of the assets discontinued entirely. Ipsen has set aside the two drug candidates it picked up from a 2023 acquisition of liver disease specialist Albireo, with one of the assets discontinued entirely. Biotech Cell & Gene Therapy Clinical Data Venture Capital Deals Research Medtech Devices Diagnostics AI and Machine Learning CRO Special Reports Trending Biologics Clinical Development Ophthalmology Cell & Gene Therapy Fierce 50 Special Report Awards Gala Awards Outsourcing Awards Innovation Awards Resources Fierce Events Industry…

Source: FierceBiotech